Axovant Sciences Ltd. (NASDAQ:AXON) – Analysts at Oppenheimer Holdings lowered their Q3 2018 EPS estimates for Axovant Sciences in a note issued to investors on Sunday. Oppenheimer Holdings analyst J. Olson now anticipates that the biotechnology company will earn ($0.54) per share for the quarter, down from their prior estimate of ($0.51). Oppenheimer Holdings currently has a “Hold” rating on the stock. Oppenheimer Holdings also issued estimates for Axovant Sciences’ Q4 2018 earnings at ($0.51) EPS, FY2018 earnings at ($2.34) EPS, FY2019 earnings at ($2.00) EPS, FY2020 earnings at ($1.54) EPS and FY2022 earnings at ($0.79) EPS.
A number of other analysts also recently issued reports on the stock. BidaskClub downgraded shares of Axovant Sciences from a “sell” rating to a “strong sell” rating in a report on Friday, September 15th. Evercore ISI initiated coverage on shares of Axovant Sciences in a research report on Friday, September 8th. They set an “outperform” rating and a $30.00 price target on the stock. Zacks Investment Research upgraded shares of Axovant Sciences from a “hold” rating to a “strong-buy” rating and set a $8.00 price target on the stock in a research report on Monday, October 9th. HC Wainwright reiterated a “buy” rating on shares of Axovant Sciences in a research report on Thursday, October 19th. Finally, Chardan Capital restated a “sell” rating and issued a $3.00 price objective on shares of Axovant Sciences in a report on Saturday, September 23rd. Four analysts have rated the stock with a sell rating, five have given a hold rating and six have given a buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average price target of $14.13.
WARNING: “Axovant Sciences Ltd. to Post Q3 2018 Earnings of ($0.54) Per Share, Oppenheimer Holdings Forecasts (AXON)” was reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this news story on another publication, it was stolen and republished in violation of United States and international trademark and copyright legislation. The correct version of this news story can be viewed at https://www.dispatchtribunal.com/2017/11/15/axovant-sciences-ltd-to-post-q3-2018-earnings-of-0-54-per-share-oppenheimer-holdings-forecasts-axon.html.
Axovant Sciences (NASDAQ AXON) traded up $0.05 on Wednesday, hitting $5.16. 581,600 shares of the stock were exchanged, compared to its average volume of 1,033,010. Axovant Sciences has a 12-month low of $4.60 and a 12-month high of $27.98. The company has a quick ratio of 5.94, a current ratio of 5.94 and a debt-to-equity ratio of 0.34.
Axovant Sciences (NASDAQ:AXON) last released its quarterly earnings data on Monday, August 7th. The biotechnology company reported ($0.65) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.53) by ($0.12).
A number of hedge funds have recently added to or reduced their stakes in the business. Wells Fargo & Company MN lifted its position in Axovant Sciences by 1.6% during the second quarter. Wells Fargo & Company MN now owns 22,790 shares of the biotechnology company’s stock valued at $528,000 after purchasing an additional 355 shares during the last quarter. American International Group Inc. lifted its holdings in Axovant Sciences by 7.1% during the 1st quarter. American International Group Inc. now owns 15,052 shares of the biotechnology company’s stock valued at $225,000 after buying an additional 998 shares in the last quarter. Legal & General Group Plc lifted its holdings in Axovant Sciences by 20.2% during the 2nd quarter. Legal & General Group Plc now owns 6,955 shares of the biotechnology company’s stock valued at $162,000 after buying an additional 1,168 shares in the last quarter. Bank of America Corp DE lifted its holdings in Axovant Sciences by 38.9% during the 1st quarter. Bank of America Corp DE now owns 7,396 shares of the biotechnology company’s stock valued at $111,000 after buying an additional 2,072 shares in the last quarter. Finally, Russell Investments Group Ltd. lifted its holdings in Axovant Sciences by 38.5% during the 2nd quarter. Russell Investments Group Ltd. now owns 10,041 shares of the biotechnology company’s stock valued at $233,000 after buying an additional 2,789 shares in the last quarter.
Axovant Sciences Company Profile
Axovant Sciences Ltd. is a clinical-stage biopharmaceutical company. The Company is focused on acquiring, developing and commercializing therapeutics for the treatment of dementia, including Alzheimer’s disease and Lewy body dementia. The Company intends to develop a pipeline of product candidates to address the cognitive, functional and behavioral aspects of dementia and related neurological disorders.
Receive News & Ratings for Axovant Sciences Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axovant Sciences Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.